PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Mechanism of Action
PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system.
Dosage Overview
Dose Range
1.8 mg
Route
subcutaneous
Frequency
Weekly
Cycle Length
4–12 weeks
Reconstitution
Typical Dosage (Research)
FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month.
Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols.
Considerations for Men & Women
Women: FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered subcutaneously at least 45 minutes before anticipated sexual activity. May cause transient increases in blood pressure, nausea, and skin flushing. Not for use with hormonal contraceptives that rely on GnRH pathways.
Men: Used off-label for erectile dysfunction, particularly in cases unresponsive to PDE5 inhibitors. Works via central melanocortin pathways rather than vascular mechanisms, making it a different approach from Viagra/Cialis. Typical research doses are lower than female HSDD protocols.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Concentration: 5 mg/ml
Volume to inject: 0.35 ml
Syringe units (U-100): 35.0 units
Pre-filled with PT-141 (Bremelanotide) defaults. Adjust values as needed.
Side Effects & Risks
Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur.
Not recommended for use with alcohol. May cause significant nausea. Should not be used in patients with uncontrolled hypertension or cardiovascular disease.
Who Uses PT-141 (Bremelanotide)
Women with HSDD (approved use), researchers studying sexual function, individuals exploring libido enhancement.
Frequently Asked Questions
Similar Peptides
View All Alternatives →Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme found in every living cell. It plays a central role in energy metabolism, DNA repair, gene expression, and cellular signaling. NAD+ levels naturally decline with age, and restoring them has become a major focus of longevity research. Injectable NAD+ bypasses the GI tract for higher bioavailability compared to oral precursors like NMN or NR.
Cortexin is a polypeptide complex derived from pig brain cortex, used clinically in Russia and Eastern Europe for neurological conditions including stroke recovery, traumatic brain injury, and cognitive decline.
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.